Key Highlights
- Fennec Pharmaceuticals (TSX:FRX) rose 6.2% to CAD 14.76 in the October 22, 2026 session, from a prior close near CAD 13.90, simple arithmetic on the published change and the quote.
- Second-quarter 2026 net product sales were USD 17.1 million, up 78% from USD 9.7 million in the second quarter of 2025. That is a revenue gain of USD 7.4 million, simple subtraction.
- Adjusted EBITDA turned positive at USD 2.8 million, against a loss of USD 1.2 million a year earlier, in results published on August 11, 2026.
- Cash and equivalents were USD 41.2 million at June 30, 2026, up from USD 40.1 million at March 31, 2026, with no company release found for October 20 to 22.
What Moved the Shares
No Fennec Pharmaceuticals release dated October 20 to 22, 2026 was found, so the 6.2% gain is written as a move without a confirmed catalyst. A prior close near CAD 13.90 is simple arithmetic on two published numbers. The latest results were published on August 11, 2026, and a third-quarter report date had not been confirmed in material found. Possible explanations include positioning ahead of that report, a broader bid for small healthcare companies or simple trading in a thin stock. None of these was verified for the session. The shares also trade on Nasdaq, so the Canadian quote reflects the exchange rate as well. Thin liquidity can also magnify moves in the Canadian line.
PEDMARK and the Second Quarter
The company sells PEDMARK, a treatment used to reduce the risk of ototoxicity, or hearing loss, linked to cisplatin chemotherapy in certain pediatric patients. Second-quarter net product sales rose 78% to USD 17.1 million, and adjusted EBITDA swung to a USD 2.8 million profit from a USD 1.2 million loss, a sign that revenue growth is outpacing operating costs. Cash of USD 41.2 million at June 30 was slightly above the USD 40.1 million at March 31, so the business funded its own growth during the quarter, though a full cash flow statement was not reviewed here. Because the company sells a single product, quarterly sales swings can move the shares sharply.
Risks and What to Watch
Dependence on a single product is the main risk: reimbursement changes, competition from alternative treatments, supply issues or slower prescriber uptake could reduce sales quickly. A small patient population limits the ceiling for growth, and a company with USD 41.2 million of cash has limited room to absorb setbacks. A 6.2% gain without news can fade. Watch for the third-quarter report, sales growth against the 78% second-quarter pace, adjusted EBITDA margin, any label expansion or international approvals and the cash balance before concluding that profitability is durable. Competing treatments, payer coverage decisions and the small number of eligible patients can all shape how fast sales grow from here.
Where Things Stand
Fennec Pharmaceuticals (TSX:FRX) is up 6.2% without a confirmed catalyst. The balance of evidence is positive on the business but unexplained for the day: PEDMARK sales rose 78% in the second quarter and adjusted EBITDA turned positive, yet no October release explains the move, and the company relies on one product. The next marker is the third-quarter report, whose date had not been confirmed in material found, so the gain should be treated as unconfirmed momentum. Cash of USD 41.2 million gives some cushion.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...